These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 23154555)

  • 21. Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.
    Fang H; Lin RY; Sun MX; Wang Q; Zhao YL; Yu JL; Tian Y; Wang XY
    Asian Pac J Cancer Prev; 2014; 15(24):10967-70. PubMed ID: 25605210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04).
    Iranzo V; Sirera R; Carrato A; Cabrera A; Jantus E; Guijarro R; Sanmartín E; Blasco A; Gil M; Gómez-Aldaraví L; González-Larriba JL; Massuti B; Velasco A; Provencio M; Rossell R; Camps C
    Clin Transl Oncol; 2011 Jun; 13(6):411-8. PubMed ID: 21680302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
    Scagliotti GV; De Marinis F; Rinaldi M; Crinò L; Gridelli C; Ricci S; Zhao YD; Liepa AM; Peterson P; Tonato M
    J Thorac Oncol; 2009 Dec; 4(12):1568-71. PubMed ID: 20009911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial.
    Hsu C; Kuo SH; Hu FC; Cheng AL; Shih JY; Yu CJ; Lin CC; Huang TC; Yang PC; Yang CH
    Lung Cancer; 2008 Dec; 62(3):334-43. PubMed ID: 18450322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
    Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
    Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.
    Gridelli C; Morgillo F; Favaretto A; de Marinis F; Chella A; Cerea G; Mattioli R; Tortora G; Rossi A; Fasano M; Pasello G; Ricciardi S; Maione P; Di Maio M; Ciardiello F
    Ann Oncol; 2011 Jul; 22(7):1528-1534. PubMed ID: 21212155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.
    Yang JC; Hirsh V; Schuler M; Yamamoto N; O'Byrne KJ; Mok TS; Zazulina V; Shahidi M; Lungershausen J; Massey D; Palmer M; Sequist LV
    J Clin Oncol; 2013 Sep; 31(27):3342-50. PubMed ID: 23816967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
    Papadimitrakopoulou VA; Soria JC; Jappe A; Jehl V; Klimovsky J; Johnson BE
    J Thorac Oncol; 2012 Oct; 7(10):1594-601. PubMed ID: 22968184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer.
    Uramoto H; Nakanishi R; Nagashima A; Uchiyama A; Inoue M; Osaki T; Yoshimatsu T; Sakata H; Nakanishi K; Yasumoto K
    Anticancer Res; 2010 Nov; 30(11):4695-9. PubMed ID: 21115926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial.
    Reck M; Socinski MA; Luft A; Szczęsna A; Dediu M; Ramlau R; Losonczy G; Molinier O; Schumann C; Gralla RJ; Bonomi P; Brown J; Soldatenkova V; Chouaki N; Obasaju C; Peterson P; Thatcher N
    J Thorac Oncol; 2016 Jun; 11(6):808-18. PubMed ID: 26980471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer.
    Gridelli C; Rossi A; Di Maio M; Leo S; Filipazzi V; Favaretto AG; Burgio MA; Cinieri S; Bianco R; Ciardiello F; Cavanna L; Bordonaro R; Costanzo R; Sandomenico C; Gallo C; Perrone F; Morabito A
    Clin Lung Cancer; 2014 Mar; 15(2):166-70. PubMed ID: 24418693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study.
    Biesma B; Wymenga ANM; Vincent A; Dalesio O; Smit HJM; Stigt JA; Smit EF; van Felius CL; van Putten JWG; Slaets JPJ; Groen HJM;
    Ann Oncol; 2011 Jul; 22(7):1520-1527. PubMed ID: 21252061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Impact of erlotinib treatment on symptoms and quality of life in patients with advanced non-small-cell lung cancer].
    Zhou SW; Ren SX; Yan LH; Zhang L; Zhou CC
    Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):469-72. PubMed ID: 19024526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2
    Zhong WZ; Chen KN; Chen C; Gu CD; Wang J; Yang XN; Mao WM; Wang Q; Qiao GB; Cheng Y; Xu L; Wang CL; Chen MW; Kang X; Yan W; Yan HH; Liao RQ; Yang JJ; Zhang XC; Zhou Q; Wu YL
    J Clin Oncol; 2019 Sep; 37(25):2235-2245. PubMed ID: 31194613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer.
    Syrigos KN; Vansteenkiste J; Parikh P; von Pawel J; Manegold C; Martins RG; Simms L; Sugarman KP; Visseren-Grul C; Scagliotti GV
    Ann Oncol; 2010 Mar; 21(3):556-561. PubMed ID: 19828561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group.
    Gridelli C; Gallo C; Shepherd FA; Illiano A; Piantedosi F; Robbiati SF; Manzione L; Barbera S; Frontini L; Veltri E; Findlay B; Cigolari S; Myers R; Ianniello GP; Gebbia V; Gasparini G; Fava S; Hirsh V; Bezjak A; Seymour L; Perrone F
    J Clin Oncol; 2003 Aug; 21(16):3025-34. PubMed ID: 12837810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study.
    Wu YL; Zhou C; Lu S; Qin S; Pan H; Wu G; Cheng Y; Liu X; Han B; Zhu Y; Zhong Z; Huang C; Chen L; Liang H; Li E; Jiang G
    Lung Cancer; 2019 Apr; 130():18-24. PubMed ID: 30885342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.
    Scagliotti G; Brodowicz T; Shepherd FA; Zielinski C; Vansteenkiste J; Manegold C; Simms L; Fossella F; Sugarman K; Belani CP
    J Thorac Oncol; 2011 Jan; 6(1):64-70. PubMed ID: 21119545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
    Edelman MJ; Clark JI; Chansky K; Albain K; Bhoopalam N; Weiss GR; Giguere JK; Kelly K; Crowley J; Gandara DR
    Clin Cancer Res; 2004 Aug; 10(15):5022-6. PubMed ID: 15297403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
    Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.